An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development

Cancer Research

Volumn 65, Issue 21, 2005, Pages 9633-9636

  Cullinane, Carleen ^a   Dorow, Donna S ^a   Kansara, Maya ^a   Conus, Nelly ^a   Binns, David ^a   Hicks, Rodney J ^a   Ashman, Leonie K ^c   McArthur, Grant A ^a,b   Thomas, David M ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; FLUORODEOXYGLUCOSE; GLUCOSE; GLUCOSE TRANSPORTER 1; GLYCINE; IMATINIB; VALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL METABOLISM; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GLUCOSE TRANSPORT; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE C KIT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; FEMALE; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED DBA; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 27544494166     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2285     Document Type: Article

References (19)

1. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22: 3813-25.
2. Demetri G. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol 2001;28:19-26.
3. Stroobants S, Goeminne J, Seegers M. et al. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003;39:2012-20.
4. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005;128:270-9.
5. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.
6. Krupka RM, Deves R. An experimental test for cyclic versus linear transport models. The mechanisms of glucose and choline transport in erythrocytes. J Biol Chem 1981;256:5410-6.
7. Nefesh I, Bauskin AR, Alkalay I, Golembo M, Ben-Neriah Y. IL-3 facilitates lymphocyte hexose transport by enhancing the intrinsic activity of the transport system. Int Immunol 1991;3:827-31.
8. Chiang S, Cardi C, Matej S, et al. Clinical validation of fully 3-D versus 2.5-D RAMLA reconstruction on the Philips-ADAC CPET PET scanner. Nucl Med Commun 2004;25:1103-7.
9. Tanaka E, Kudo H. Subset-dependent relaxation in block-iterative algorithms for image reconstruction in emission tomography. Phys Med Biol 2003;48:1405-22.
10. Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit where- as the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 2002;1:1115-24.
11. Joost HG, Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members [review]. Mol Membr Biol 2001;18: 247-56.
12. Warburg O, editor. In: The metabolism of tumors. New York: Richard Smith, Inc.; 1931.
13. Kumar S, Vaux DL. Apoptosis. A Cinderella caspase takes center stage. Science 2002;297:1290-1.
14. Plas DR, Thompson CB. Cell metabolism in the regulation of programmed cell death. Trends Endocrinol Metab 2002;13:75-8.
15. Elstrom RL, Bauer DE, Buzzai M, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004;64: 3892-9.
16. Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB. Aid-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol 2003; 23:7315-28.
17. Denny WA. The role hypoxia-activated prodrugs in cancer therapy. Lancet Oncol 2000;1:25-9.
18. Moadel RM, Weldon RH, Katz EB, et al. Positherapy: targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-D-glucose. Cancer Res 2005;65: 698-702.
19. Niculescu-Duvaz I. Glufosfamide (Baxter oncology). Curr Opin Investig Drugs 2002;3:1527-32.